Form 4: Cytek Biosciences' CTO Ming Yan Sells Shares Under 10b5-1 Trading Plan
SEC Form 4 Filing
Ming Yan, Chief Technology Officer of Cytek Biosciences, sold 1,900 shares of common stock on April 9, 2024, under a pre-arranged Rule 10b5-1 trading plan.
Summary
- On April 9, 2024, Ming Yan, the Chief Technology Officer of Cytek Biosciences, sold 1,500 shares of common stock at $7 per share and 400 shares at $7.01 per share.
- These transactions were executed under a Rule 10b5-1 trading plan adopted on November 30, 2023.
- Following these sales, Yan directly owns 6,008,502 shares of Cytek Biosciences common stock.
Sentiment
Score: 5
Explanation: The sentiment is neutral as the filing simply reports stock sales under a pre-arranged trading plan, which is a common and legal practice.
Industry Context
Sales by insiders are a common occurrence and are often pre-planned through Rule 10b5-1 trading plans to avoid accusations of trading on inside information. The market typically views these sales in the context of the overall health and prospects of the company.
Stakeholder Impact
- The stock sale could have a minor impact on shareholders, potentially causing a slight decrease in stock price due to increased supply.
Key Dates
| Date | Description |
|---|---|
| 2023-11-30 | Date of adoption of Rule 10b5-1 trading plan |
| 2024-04-09 | Date of stock sale transactions |
| 2024-04-11 | Date of Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.